Category: Cannabis

Verano Sees Losses Widen In Q4 After Impairing Assets

Verano Holdings (CSE: VRNO) has saw its revenue growth flatline in the fourth quarter, with the company reporting this morning that the quarter saw a 1% decline in net revenue versus the third quarter.

Revenue overall came in at $225.9 million, down 1% from the $227.6 million reported in the third quarter, but up 7% from the $211.4 million reported in the fourth quarter of 2021. The year over year growth was attributed to success in the New Jersey market, as well as store growth in Florida.

Gross profit however declined rather substantially, falling to $103.3 million in Q4, a 16% decline from the third quarter and a 5% decline from a year ago, with the poor performance blamed on discounting and cost increases from expansion. The figure represents 46% of revenue, down from 54% in the prior quarter.

After SG&A expenses of $81.0 million, and impairments to goodwill of $113.0 million and impairments to intangibles of $116.2 million, the firm reported an operating loss of $207.0 million, leading to an overall net loss of $216.1 million, versus a loss of $43.0 million in the prior quarter and a loss of $7.4 million in the year ago period. Adjusted EBITDA meanwhile came in at $78.7 million.

READ: Tobacco (Finally) Falls Out of Favor As Legal Marijuana Continues to Gain Public Support

On a full year basis, the company saw revenues increase 19% to $879.4 million, with gross profits of $423.1 million. SG&A expenses amounted to $356.6 million, and after the aforementioned impairments, the firm reported an operating loss of $161.1 million and a net loss of $269.2 million, versus a loss of $57.5 million in the prior year.

Adjusted EBITDA for the full fiscal year meanwhile was reported at $323.6 million.

In terms of cash, the firm finished the year off with $84.9 million in cash and cash equivalents, down from $99.1 million at the start of the year.

Verano Holdings last traded at $3.81 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Tilray Brands Q3 Earnings Analysis: Behind The CEO’s “Robust” Claims

April 12, 2025, 03:28:00 PM

Tilray Q3 FY2025 Results: Shares Slump On 656% Wider Net Loss

April 10, 2025, 07:21:00 AM

Gold Flora Corp Files for Voluntary Receivership Amid Mounting Debt

March 31, 2025, 08:00:13 AM

SNDL Reports Record Annual Revenue in 2024, But Still Posts An Operating Loss

March 18, 2025, 11:29:00 AM

Simply Solventless To Acquire CanadaBis Capital For $0.116 A Share In All-Stock Deal

March 12, 2025, 09:08:11 AM

Trulieve Cannabis Sees Another CFO Resign

March 7, 2025, 08:48:47 AM

Curaleaf Reports $216M Net Loss in 2024 Despite $1.34B Revenue

March 4, 2025, 08:01:00 AM

Fetterman Launches Petition Drive for Federal Marijuana Legalization

February 26, 2025, 10:04:00 AM

Acting DEA Chief Says Cannabis Review Is Not Dead—Yet—as Successor Looms

February 12, 2025, 12:47:00 PM

Aurora Cannabis Rallies On 316% Earnings Jump In Q3 2025

February 9, 2025, 11:28:00 AM
Video Articles

Teck Resources Q1 Earnings: Defying Copper Industry Weakness

Equinox Ups Its Offer For Calibre: Investors Said No!

First Quantum Q1 Earnings: Copper Major Still Bleeding Cash

Recommended

Verses Hits Commercialization Stage With Genius AI Platform

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial